South Korea Prodded To Ease Restrictions On OTC Drugs, Other Rules
This article was originally published in PharmAsia News
Executive SummarySouth Korea's government was urged by a think tank to change its regulations to ease some restrictions on the sale of pharmaceuticals, such as over-the-counter versions
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.